157284-96-3Relevant articles and documents
Pyrrolopyrimidines as CRF antagonists
-
, (2008/06/13)
The compounds of the formula wherein R1, R2, R3, R4, R5and R6are as defined herein, are useful in the treatment of stress-related and other diseases. These compounds have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of stress and anxiety related, and other disorders.
Use of CRF antagonists and renin-angiotensin system inhibitors
-
, (2008/06/13)
The present invention relates to compositions and methods of achieving a therapeutic effect including, but not limited to, the treatment of congestive heart failure or hypertension in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin releasing factor (CRF) antagonist and a renin-angiotensin system (RAS) inhibitor.
QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
-
, (2008/06/13)
A method of preventing sudden death which comprises administering to a mammal, including a human, a therapeutically effective amount of a corticotropin releasing factor antagonist.
New uses for corticotropin releasing factor antagonists
-
, (2008/06/13)
A method of treating, preventing or inhibiting a disorder selected from the group consisting of cardiovascular or heart related diseases such as stroke, hypertension, tachycardia, and congestive heart failure, osteoporosis, premature birth, psychosocial dwarfism, stress-induced fever, ulcer, diarrhea, post-operative ileus, and colonic hypersensitivity associated with psychopathological disturbance and stress, comprising administering to a mammal, including a human, in need of such treatment a therapeutically effective amount of a compound of the formula or pharmaceutically acceptable salt thereof, wherein A, B, D, E, Y, Z, R3, R4, and R5 are as defined herein.
PYRAZOLOPYRIMIDINES FOR TREATMENT OF CNS DISORDERS
-
, (2008/06/13)
This invention relates to the use of pyrazolopyrimidines and pyrrolopyrimidine of, respectively, the general formula STR1 wherein A, X, R 3, R 4 and R 5 are as defined below, and the pharmaceutically acceptable salts of such compounds, to treat, prevent or inhibit certain neuronal and other disorders.
Methods of administering CRF antagonists
-
, (2008/06/13)
Compounds of the formula STR1 wherein B, R3, R4, R5 and R6 are as defined herein with reference to formula IX have corticotropin-releasing factor antagonist activity and as such are of use in the treatment of panics, phobias and other stress-related disorders.